ERBB2 and triple-negative breast carcinoma: In the past decade, NACT has evolved from an option for locally advanced cancers to a standard curative modality for up to 60% of patients with human epidermal growth factor receptor-2 (HER2) positive and triple-negative breast cancer (TNBC) [2].